ProQR Therapeutics (PRQR) IPO Opens Sharply Higher

Today's IPO for ProQR Therapeutics B.V. (NASAQ: PRQR) opened for trading at $19 after pricing 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share, the high end of the expected $11-$13 range. Shares immediately zoomed to $21.65.

Leerink Partners and Deutsche Bank Securities are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager, and H.C. Wainwright & Co., LLC is acting as co-manager for the offering.

ProQR Therapeutics B.V. is an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis. Utilizing our unique, proprietary RNA repair technologies, they believe they will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation. They believe that this is a unique approach that offers advantages compared with small molecule, gene therapy and other therapeutic strategies.

You May Also Be Interested In

• Ancora Sends Important Letter to Fellow Shareholders on Norfolk Southern (NSC) Turnaround Plan
• Vertex (VERX) Reports Prelim Q1 Results
• Momentus Inc. (MNTS) Receives Nasdaq Deficiency Notice